Transcept Pharmaceuticals to Present at Jefferies Global Life Sciences Conference on June 10, 2010

Jun 03, 2010, 16:05 ET from Transcept Pharmaceuticals, Inc.

POINT RICHMOND, Calif., June 3 /PRNewswire-FirstCall/ -- Transcept Pharmaceuticals, Inc.  (Nasdaq: TSPT), a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience, today announced Transcept management is scheduled to present a general business overview and product pipeline update at the Jefferies 2010 Global Life Sciences Conference in New York on Thursday, June 10th, at 8:30 a.m. Eastern Time.

A live audio webcast and replay of the presentation will be available at http://www.wsw.com/webcast/jeff46/tspt and on the Transcept Investor webpage at www.transcept.com.

About Transcept

Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience.  The most advanced Transcept product candidate is Intermezzo® (zolpidem tartrate sublingual tablet), for which a New Drug Application (NDA) was submitted to the U.S. Food and Drug Administration (FDA) in September 2008 seeking approval as a prescription sleep aid for use in the middle of the night at the time a patient awakens and has difficulty returning to sleep. In October 2009, Transcept received a Complete Response Letter from the FDA on the Intermezzo® NDA and is working to respond to issues raised in the letter.  Transcept and Purdue Pharmaceutical Products, L.P. have entered into a collaboration agreement for the development and commercialization of Intermezzo® in the United States.  For further information, please visit the company's website at: www.transcept.com.

Contact:

Transcept Pharmaceuticals, Inc.

Greg Mann

Director, Corporate Communications

(510) 215-3567

gmann@transcept.com

SOURCE Transcept Pharmaceuticals, Inc.



RELATED LINKS

http://www.transcept.com